رشا عمر عبد المنعم احمد
أستاذ مساعد
Lipoprotein (A) In Type 2 Diabetes Mellitus as A Marker of Atherosclerotic Cardiovascular Disease
• 2026
معلومات البحث
المؤلفون
Amira M. Elsayed*, Rasha O. Abdelmoniem, Hend R. Aboelfotouh, Walaa M. lbrahim
الكلمات المفتاحية
Not Available
المجلة العلمية
Not Available
الناشر
Not Available
المجلد
Not Available
العدد
Not Available
الصفحات
Not Available
publication.type
Local
رابط البحث
Not Available
المواد المرفقة
Not Available
الملخص
Background: One of the most important complications of Type 2 diabetes mellitus (T2DM) is atherosclerotic
cardiovascular disorders (ASCVD), a disease that affects a large percentage of the population and considered a
healthcare burden. Objective: Our aim to establish a probable relationship between lipoprotein (a) [Lp (a)] and T2DM
and to demonstrate it as a marker of (ASCVD).
Patients and Methods: This case-control study included 200 subjects; 150 diabetic patients and 50 age and gender
matched healthy subjects. Thorough history taking of T2DM with assessment of vascular diabetic complications was
done. The fasting plasma glucose, HbA1c, lipid profile, s. creatinine and Lp (a) level were performed to all participants.
Results: Lp (a) levels were significantly low in diabetic patients (19.8 ± 13.4 mg/dl) compared to control group (32.6 ±
20.8 mg/dl) (p
cardiovascular disorders (ASCVD), a disease that affects a large percentage of the population and considered a
healthcare burden. Objective: Our aim to establish a probable relationship between lipoprotein (a) [Lp (a)] and T2DM
and to demonstrate it as a marker of (ASCVD).
Patients and Methods: This case-control study included 200 subjects; 150 diabetic patients and 50 age and gender
matched healthy subjects. Thorough history taking of T2DM with assessment of vascular diabetic complications was
done. The fasting plasma glucose, HbA1c, lipid profile, s. creatinine and Lp (a) level were performed to all participants.
Results: Lp (a) levels were significantly low in diabetic patients (19.8 ± 13.4 mg/dl) compared to control group (32.6 ±
20.8 mg/dl) (p
